JP2010523591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523591A5 JP2010523591A5 JP2010502312A JP2010502312A JP2010523591A5 JP 2010523591 A5 JP2010523591 A5 JP 2010523591A5 JP 2010502312 A JP2010502312 A JP 2010502312A JP 2010502312 A JP2010502312 A JP 2010502312A JP 2010523591 A5 JP2010523591 A5 JP 2010523591A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- item
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 239000000460 chlorine Substances 0.000 claims description 15
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 239000011737 fluorine Substances 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000001475 halogen functional group Chemical group 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
- -1 cyano, carbonyl Chemical group 0.000 claims description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 8
- 241000713124 Rift Valley fever virus Species 0.000 claims description 6
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 2
- QYNRHOUBXYWNDP-UHFFFAOYSA-N C(CC1)CN1c(cc1)cc(Sc2c3)c1Nc2ccc3N1CCCC1 Chemical compound C(CC1)CN1c(cc1)cc(Sc2c3)c1Nc2ccc3N1CCCC1 QYNRHOUBXYWNDP-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90992807P | 2007-04-03 | 2007-04-03 | |
| PCT/US2008/059326 WO2008124550A1 (en) | 2007-04-03 | 2008-04-03 | Phenothiazin derivatives for antiviral treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523591A JP2010523591A (ja) | 2010-07-15 |
| JP2010523591A5 true JP2010523591A5 (enExample) | 2012-05-24 |
Family
ID=39718949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502312A Pending JP2010523591A (ja) | 2007-04-03 | 2008-04-03 | 抗ウイルス処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8227459B2 (enExample) |
| EP (1) | EP2137172A1 (enExample) |
| JP (1) | JP2010523591A (enExample) |
| CN (1) | CN101631780A (enExample) |
| AU (1) | AU2008237276A1 (enExample) |
| CA (1) | CA2686513C (enExample) |
| WO (1) | WO2008124550A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010299571B2 (en) * | 2009-09-24 | 2014-07-31 | TauRx Therapeutics Management Ltd | Crystalline methylthionium chloride (methylene blue) hydrates |
| AU2016202982B2 (en) * | 2009-09-24 | 2017-09-21 | TauRx Therapeutics Management Ltd | Crystalline methylthionium chloride (methylene blue) hydrates |
| CN102958525B (zh) * | 2010-04-30 | 2017-05-24 | 普罗瑟塔抗病毒股份有限公司 | 抗病毒化合物 |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| WO2012125983A1 (en) | 2011-03-17 | 2012-09-20 | Prosetta Antiviral Inc. | Antiviral treatments |
| WO2012135402A1 (en) * | 2011-03-29 | 2012-10-04 | Prostetta Antiviral Inc. | Antiviral compounds |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| US10153510B2 (en) | 2014-06-23 | 2018-12-11 | University Of Kentucky Research Foundation | Non-aqueous redox flow batteries including 3,7-perfluoroalkylated phenothiazine derivatives |
| US9518022B2 (en) * | 2014-12-15 | 2016-12-13 | Prosetta Antiviral Inc. | Anti-HIV compounds |
| CN114605267B (zh) * | 2022-03-18 | 2024-02-23 | 北京格林凯默科技有限公司 | 2-溴-n,n-二甲基苯胺的制备方法 |
| EP4651874A2 (en) * | 2023-02-21 | 2025-11-26 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19640758C2 (de) * | 1996-10-02 | 1999-11-04 | Rafael Lachky | Mittel zur Behandlung von Diskusfischen |
| GB0113121D0 (en) * | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
| KR20060111536A (ko) * | 2003-11-28 | 2006-10-27 | 포토파미카 리미티드 | 생물학적 활성 메틸렌 블루 유도체(２)의 개발 |
| US20080166304A1 (en) * | 2004-09-17 | 2008-07-10 | The General Hospital Corpoartion | Inactivation of Microorganisms With Multidrug Resistance Inhibitors and Phenothiaziniums |
| GB0420888D0 (en) * | 2004-09-20 | 2004-10-20 | Photopharmica Ltd | Compounds and uses |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| PT2013191E (pt) * | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | Sais de 3,7-diamino-10h-fenotiazina e a sua utilização |
-
2008
- 2008-04-03 CA CA2686513A patent/CA2686513C/en not_active Expired - Fee Related
- 2008-04-03 WO PCT/US2008/059326 patent/WO2008124550A1/en not_active Ceased
- 2008-04-03 AU AU2008237276A patent/AU2008237276A1/en not_active Abandoned
- 2008-04-03 JP JP2010502312A patent/JP2010523591A/ja active Pending
- 2008-04-03 CN CN200880008338A patent/CN101631780A/zh active Pending
- 2008-04-03 US US12/062,491 patent/US8227459B2/en active Active
- 2008-04-03 EP EP08745055A patent/EP2137172A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523591A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2009531376A5 (enExample) | ||
| JP2009531403A5 (enExample) | ||
| TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| JP2005053931A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| UY27466A1 (es) | Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides | |
| MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
| JP2013545785A5 (enExample) | ||
| JP2013541514A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| JP2011500545A5 (enExample) | ||
| JP2010510233A5 (enExample) | ||
| JP2016501250A5 (enExample) | ||
| JP2008523082A5 (enExample) | ||
| JP2010510967A5 (enExample) | ||
| WO2007038507A3 (en) | Modified 4'-nucleosides as antiviral agents | |
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2010529147A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2005525392A5 (enExample) | ||
| JP2006513205A5 (enExample) | ||
| JP2018537535A5 (enExample) | ||
| JP2019501927A5 (enExample) |